Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : TB Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : TB Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment
Details : Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.
Product Name : Rifapentine/Isoniazid-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
July 10, 2022
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases | Aurum Institute | A*STAR | University of Cape Town | Wits Health Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2021
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : National Institute of Allergy and Infectious Diseases | Aurum Institute | A*STAR | University of Cape Town | Wits Health Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoniazid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Healing of Ischemic Leg Ulcers in Patients Treated With iSONIAzid
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2021
Lead Product(s) : Isoniazid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr
Deal Size : Inapplicable
Deal Type : Inapplicable
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2016
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : National Defense Medical Center, Taiwan | NRPB, Taiwan
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2015
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : National Defense Medical Center, Taiwan | NRPB, Taiwan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Shanghai Center for Disease Control and Prevention | Jiangsu Province Centers for Disease Control and Prevention | Zhejiang University | Centers for Disease Control and Prevention
Deal Size : Inapplicable
Deal Type : Inapplicable
Research on New Regimens for Retreatment Pulmonary Tuberculosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2015
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Shanghai Center for Disease Control and Prevention | Jiangsu Province Centers for Disease Control and Prevention | Zhejiang University | Centers for Disease Control and Prevention
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2011
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Cellestis
Deal Size : Inapplicable
Deal Type : Inapplicable
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2010
Lead Product(s) : Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Cellestis
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
